What is Kestra Medical Technologies, Ltd.'s market cap?

Kestra Medical Technologies, Ltd. (KMTS) has a market capitalization of $1.4B and trades on NASDAQ.

What is Kestra Medical Technologies, Ltd.'s revenue and profitability?

Kestra Medical Technologies, Ltd. generated $95.1M in trailing twelve-month revenue with a net loss of $131.6M, representing a net margin of -138.4%. Gross margin stands at 51.4%, with free cash flow of -$116.6M. These figures are based on the Q2 2026 filing.

Who are Kestra Medical Technologies, Ltd.'s competitors?

Kestra Medical Technologies, Ltd.'s key competitors include Boston Scientific, Medtronic, Abbott Laboratories, and others. These companies compete in similar markets and product categories.

Who does Kestra Medical Technologies, Ltd. partner with?

Kestra Medical Technologies, Ltd.'s notable partners include Zoll Medical Corporation.

What subsidiaries does Kestra Medical Technologies, Ltd. have?

Kestra Medical Technologies, Ltd.'s subsidiaries include Kestra Medical Technologies, Inc..

Where is Kestra Medical Technologies, Ltd. headquartered?

Kestra Medical Technologies, Ltd. is headquartered in United States of America. It has been publicly traded since 2025.

Kestra Medical Technologies, Ltd.

KMTS

Kestra Medical Technologies is a commercial-stage medical device and digital healthcare company that develops wearable monitoring and therapeutic intervention technologies for cardiovascular disease.

Market cap

$1.4B+63.4%

Revenue$95.1M+59.0%

Net income-$131.6M-15.6%

Free cash flow-$116.6M-16.0%

EPS (diluted)-$2.42+52.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q4 2026 report

July 14, 2026

Revenue$28.6MBeat by $2.2M EPS-$0.67Miss by $0.08

Read the full report

Next report

Sep 10, 2026 (in a month)

Revenue estimate$29.0M

EPS estimate-$0.61

Financials

Q4 2026

Income statement

See full

Revenue$28.6M+66.2%

Gross profit$15.7M+105%

Operating income-$39.3M+18.4%

Net income-$38.8M+25.4%

EPS (diluted)-$0.67+57.3%

Balance sheet

See full

Cash & equivalents$99.7M-58.0%

Total debt$46.8M+5.6%

Total assets$358.5M+21.2%

Cash flow

See full

Operating cash flow-$18.7M+22.2%

CapEx$9.7M+30.8%

Free cash flow-$28.4M+9.7%

Valuation & ratios

Valuation

See full

Market cap$1.34B+63.4%

Enterprise value$1.28B—

P/S14.1×—

Profitability

See full

Gross margin51.4%+10.9pp

Operating margin-141.6%-24.0pp

Net margin-138.4%-29.7pp

FCF margin-122.6%-26.1pp

Returns & leverage

See full

Current ratio4.4×-2.3×

Competitors

By market cap

Abbott$182.00B-17.2%

Medtronic$107.81B-8.5%

Boston Scientific$67.6B-56.8%

Merit Medical Systems$4.5B-9.1%

iRhythm Holdings, Inc. $3.7B-15.8%

Kestra Medical Technologies, Ltd.$1.3B+57.8%

Heartbeam, Inc.$29.1M-32.7%

Heart Test Laboratories, Inc.$8.3M+30.8%

By revenue growth

Kestra Medical Technologies, Ltd.+59.0%

iRhythm Holdings, Inc. +27.4%

Boston Scientific+13.5%

Merit Medical Systems+11.1%

Medtronic+8.4%

Abbott+8.1%

By net margin

Boston Scientific17.48%+4.0pp

Medtronic13.2%-0.7pp

Abbott11.65%-20.8pp

Merit Medical Systems9.03%+0.2pp

iRhythm Holdings, Inc. -7.32%+10.2pp

Kestra Medical Technologies, Ltd.-138.36%+51.9pp

Profile

Kestra Medical Technologies is a commercial-stage medical device and digital healthcare company that develops wearable monitoring and therapeutic intervention technologies for cardiovascular disease. The company's core value proposition is its Cardiac Recovery System, which integrates a next-generation wearable cardioverter defibrillator with digital health solutions to improve patient compliance and outcomes for those at risk of sudden cardiac arrest. Their platform addresses unmet needs in the cardiac care continuum by prioritizing patient comfort, gender-specific design, and intelligent data connectivity.

Competitive position

Kestra is a disruptive market entrant challenging a long-standing monopoly in the wearable cardioverter defibrillator space through superior design and digital integration.

GeographiesUnited States

Customer segmentsPost-Myocardial Infarction Patients, Heart Failure Patients, Healthcare Providers, Health Insurance Payors

Business modelDevice Lease, Service-as-a-Service, Direct-to-Provider Sales

SuppliersMedical technology component suppliers, Third-party manufacturing partners, Logistics and warehousing providers

CustomersMedicare, Medicaid, Commercial health insurers, Cardiac patients

CountryUnited States of America

Listed2025

CEOBrian Webster

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitekestramedical.com

FilingsSEC EDGAR

Ask your AI about Kestra Medical Technologies, Ltd..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kestra Medical Technologies, Ltd.'s market cap?: Kestra Medical Technologies, Ltd. (KMTS) has a market capitalization of $1.4B and trades on NASDAQ.
What is Kestra Medical Technologies, Ltd.'s revenue and profitability?: Kestra Medical Technologies, Ltd. generated $95.1M in trailing twelve-month revenue with a net loss of $131.6M, representing a net margin of -138.4%. Gross margin stands at 51.4%, with free cash flow of -$116.6M. These figures are based on the Q2 2026 filing.
Who are Kestra Medical Technologies, Ltd.'s competitors?: Kestra Medical Technologies, Ltd.'s key competitors include Boston Scientific, Medtronic, Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Who does Kestra Medical Technologies, Ltd. partner with?: Kestra Medical Technologies, Ltd.'s notable partners include Zoll Medical Corporation.
What subsidiaries does Kestra Medical Technologies, Ltd. have?: Kestra Medical Technologies, Ltd.'s subsidiaries include Kestra Medical Technologies, Inc..
Where is Kestra Medical Technologies, Ltd. headquartered?: Kestra Medical Technologies, Ltd. is headquartered in United States of America. It has been publicly traded since 2025.